No Data
Review of the A-share consecutive board leaders in 2024: Hainan Shuangcheng Pharmaceuticals and Guangdong Songfa Ceramics both achieved 14 consecutive boards, ranking first. Daqian Ecology & Environment Group and three other stocks followed closely with 1
① The 2024 A-share market has officially closed, with a number of stocks experiencing consecutive gains, among which Hainan Shuangcheng Pharmaceuticals and Guangdong Songfa Ceramics had the most days of consecutive price increases at 14; ② Attached is the ranking of the number of consecutive price increases of A-share listed companies in 2024 (attached table).
Hainan Shuangcheng Pharmaceuticals (002693.SZ): Change of Pharmaceutical Production License.
On December 26, Gu Long Hui reported that Hainan Shuangcheng Pharmaceuticals (002693.SZ) announced that the company recently obtained the revised "Pharmaceutical Production License" issued by the Hainan Provincial Drug Administration. The main change involves the approval for the company to expand its production scope at the production address of 16 Xingguo Road, Xiuying District, Haikou City: Active Pharmaceutical Ingredients (C139, C141), with production lines being: Active Pharmaceutical Ingredient Workshop No. 2 C139 production line, C141 production line, (limited to registered declaration use). Other content remains unchanged.
Some Confidence Is Lacking In Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SZSE:002693) As Shares Slide 30%
While Hainan Shuangcheng Pharmaceuticals (SZSE:002693) Shareholders Have Made 471% in 3 Years, Increasing Losses Might Now Be Front of Mind as Stock Sheds 12% This Week
Hainan Shuangcheng Pharmaceuticals (002693.SZ): The audit and evaluation work for this trade has not yet been completed.
Grain News November 20th | Hainan Shuangcheng Pharmaceuticals (002693.SZ) announced that the trading price of the company's stocks deviated by more than 20% from November 18, 2024, to November 20, 2024, for three consecutive trading days, indicating abnormal stock trading fluctuations. The company is planning a major asset restructuring, intending to purchase 100% of the shares held by Aura Investments, Win Aiming, and 25 other trading parties through issuing shares and paying cash, and plans to issue shares to no more than 35 specific investors to raise supporting funds. The audit of this transaction,
Shuangcheng Pharmaceutical: Report for the third quarter of 2024
Here's Why Hainan Shuangcheng Pharmaceuticals (SZSE:002693) Can Afford Some Debt
No Data
